Gritstone 安全な・保証するs 基金ing for COVID-19 ワクチン against variants
Aug 17 (Reuters) - Gritstone bio Inc said on Tuesday it had entered into a 基金ing 協定 of up to $20.6 million with the 連合 for 疫病／流行性の Preparedness 革新s (CEPI) to 前進する its ワクチン program against COVID-19 variants, sending its 株 up 2.6% before the bell.
Gritstone's ワクチン is based on self-amplifying mRNA 科学（工学）技術, which uses the 団体／死体's own 機械／機構 to make antigenic protein rather than 注入するing the antigen into the 団体／死体.
Under the 協定, CEPI, which co-leads the COVAX ワクチン 株ing 施設, will 基金 an 早期に 行う／開催する／段階 熟考する／考慮する 評価するing the program's ワクチン in convalescent, and HIV 肯定的な 患者s.
The 裁判，公判 is 推定する／予想するd to start before the end of 2021, Gritstone said.
CEPI and Gritstone have agreed the ワクチン 候補者 will be made 利用できる to the COVAX 施設. (報告（する）／憶測ing by Dania Nadeem in Bengaluru; Editing by Vinay Dwivedi)
